Loading clinical trials...

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT02610140

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

The main purpose of the 15743 study is to assess efficacy and safety of anetumab ravtansine versus vinorelbine in progression free survival in patients with stage IV mesothelin overexpressing malignan...

Lead sponsor: Bayer•15 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 1

SW-682 in Advanced Solid Tumors

NCT06251310 · Advanced Solid Tumor, Mesothelioma, Malignant

RECRUITINGPhase 2

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

NCT05647265 · Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma

RECRUITING

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

NCT00242723 · Malignant Pleural Mesotheliomas NOS, Esophageal Cancers NOS, and more

RECRUITINGPhase 2

Agnostic Therapy in Rare Solid Tumors

NCT06638931 · Urachal Cancer, Parathyroid Carcinoma, and more

RECRUITINGPhase 1/2

Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma

NCT07510815 · Malignant Pleural Mesotheliomas

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 4, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment248

Start dateDec 2015

Last updatedNov 4, 2020

Condition

Mesothelioma

Locations shown

La Jolla, California

Aurora, Colorado

Norwich, Connecticut

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 4, 2020Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions